Onxeo Appoints Julien Miara as New Interim CEO

Rhea-AI Summary

Onxeo S.A. has appointed Julien Miara as interim CEO, effective January 3, 2022. Miara, with over 10 years in finance and biotechnology, aims to ensure the company aligns with its strategic plan during the CEO transition. The Board is also seeking a permanent CEO to expedite the development of AsiDNA and enhance international visibility. The company focuses on innovative oncology drugs targeting tumor DNA Damage Response, with promising studies ongoing for AsiDNA™ and OX401.

Positive

• Appointment of Julien Miara as interim CEO brings expertise in finance and biotechnology.
• Ongoing clinical studies for AsiDNA™ and OX401 show positive preliminary results.
• Strategic focus on addressing unmet medical needs in oncology.

Negative

• Transition period may introduce uncertainty for stakeholders.
• CEO search could distract from development efforts.

PARIS--(BUSINESS WIRE)-- Regulatory News:

Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), today announced the appointment of Julien Miara as interim Chief Executive Officer, effective January 3^rd, 2022, following approval from the Board of Directors.

Julien Miara is a Principal at Invus SAS, the independent adviser to Invus Public Equities, L.P. He is also member of the Board of Directors of Onxeo. He has more than 10 years of experience in Finance and biotechnology. Julien Miara will work closely with Dr. Shefali Agarwal, Chairwoman of the Board of Directors who has extensive experience in drug development, to ensure that the company is progressing according to the strategic plan laid out by the Board of Directors and prepare for a successful transition to the next CEO.

The company’s Board of Directors is actively working on recruiting Onxeo’s next CEO who will focus on bringing expeditiously AsiDNA to the patients to respond to their high unmet medical need, develop the rich pre-clinical pipeline such as OX401 and provide Onxeo with international visibility.

Dr. Agarwal said: “I look forward to working with the high performing team under the supervision of Julien Miara, in the next phase of research and development for AsiDNA. I believe that Onxeo’s scientific vision and approach will drive the continued success of the company, as we work together to deliver promising new options for patients”.

About Onxeo

Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the soughtafter field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

platON™ is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.

AsiDNA™, the first compound from platON™, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the distinctive properties of AsiDNA™, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNA™ has also shown a strong synergy with other tumor DNAdamaging agents such as chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase I study has evaluated AsiDNA™ by systemic administration (IV) in advanced solid tumors and confirmed the active doses as well as a favorable human safety profile. The ongoing DRIIV-1b extension study is evaluating the safety and efficacy of AsiDNA™ at a dose of 600 mg in combination with the reference chemotherapy, carboplatin -/+ paclitaxel, in advanced metastatic tumors. Preliminary results from both cohorts showed good tolerability, stabilization of the disease and an increase in treatment duration compared to previous treatments. The ongoing REVOCAN phase 1b/2 study evaluates the effect of AsiDNA™ on the acquired resistance to PARP inhibitor niraparib in relapsed ovarian cancer (sponsored by Gustave Roussy). A phase 1b/2 study, AsiDNA™ Children, will be initiated in 2021 to evaluate the association of AsiDNA™ with radiotherapy in children with relapsed high-grade glioma (sponsored by Institut Curie).

OX401 is a new drug candidate from platON™, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.

For more information, please visit www.onxeo.com

Forward looking statements

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the risk factors described in the most recent Company’s registration document or in any other periodic financial report and in any other press release, which are available free of charge on the websites of the Company Group (www.onxeo.com) and/or the AMF (www.amf-france.org).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005364/en/

Onxeo

Valérie Leroy, Relations Investisseurs

investors@onxeo.com

+33 1 45 58 76 00



Relations Presse

Nicolas Merigeau

NewCap

onxeo@newcap.eu

+33 1 44 71 94 98



Relations Investisseurs / Communication stratégique

Dušan Orešanský / Emmanuel Huynh

NewCap

onxeo@newcap.eu

+33 1 44 71 94 92



Investor Relations US

Brian Ritchie

LifeSci Advisors

britchie@lifesciadvisors.com

+1 212 915 2578



Certified Adviser for Nasdaq

First North Kapital Partner

www.kapitalpartner.dk

info@kapitalpartner.dk

+45 89 88 78 46

Source: Onxeo S.A.

FAQ

What is the significance of the CEO appointment at Onxeo?

The appointment of Julien Miara as interim CEO is crucial for maintaining leadership continuity and strategic focus during the transition.

When did Julien Miara assume the role of interim CEO?

Julien Miara became interim CEO of Onxeo on January 3, 2022.

What are the key projects Onxeo is focusing on?

Onxeo is focused on advancing AsiDNA and OX401, both of which target tumor DNA Damage Response.

What is the role of the Board of Directors in the CEO transition?

The Board is actively involved in recruiting a new CEO and ensuring the company adheres to its strategic development plan.

How does Onxeo plan to address unmet medical needs in oncology?

Onxeo aims to expedite the development of its therapies like AsiDNA to meet high unmet medical needs in cancer treatment.